Chinese Medicine in the Treatment of Non-alcoholic Fatty Liver Disease Based on Network Pharmacology: a Review

Overview

Journal Front Pharmacol

Date 2024 May 2

PMID 38694920

Authors

Shihao Zheng

Chengyuan Xue

Size Li

Xiaobin Zao

Xiaoke Li

Qiyao Liu

Xu Cao

Wei Wang

Wenying Qi

Peng Zhang

Yongan Ye

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological syndrome characterized by abnormalities in hepatic fat deposition, the incidence of which has been increasing year by year in recent years. It has become the largest chronic liver disease globally and one of the important causes of cirrhosis and even primary liver cancer formation. The pathogenesis of NAFLD has not yet been fully clarified. Modern medicine lacks targeted clinical treatment protocols for NAFLD, and most drugs lack efficacy and have high side effects. In contrast, Traditional Chinese Medicine (TCM) has significant advantages in the treatment and prevention of NAFLD, which have been widely recognized by scholars around the world. In recent years, through the establishment of a "medicine-disease-target-pathway" network relationship, network pharmacology can explore the molecular basis of the role of medicines in disease prevention and treatment from various perspectives, predicting the pharmacological mechanism of the corresponding medicines. This approach is compatible with the holistic view and treatment based on pattern differentiation of TCM and has been widely used in TCM research. In this paper, by searching relevant databases such as PubMed, Web of Science, and Embase, we reviewed and analyzed the relevant signaling pathways and specific mechanisms of action of single Chinese medicine, Chinese medicine combinations, and Chinese patent medicine for the treatment of NAFLD in recent years. These related studies fully demonstrated the therapeutic characteristics of TCM with multi-components, multi-targets, and multi-pathways, which provided strong support for the exact efficacy of TCM exerted in the clinic. In conclusion, we believe that network pharmacology is more in line with the TCM mindset of treating diseases, but with some limitations. In the future, we should eliminate the potential risks of false positives and false negatives, clarify the interconnectivity between components, targets, and diseases, and conduct deeper clinical or experimental studies.

Citing Articles

Exploring the mechanism of SLXG for treating nonalcoholic fatty liver disease based on network pharmacology and molecular docking.

Wang Y, Wang J, Chen Z, Liu B, Wang W, Li Y Medicine (Baltimore). 2025; 104(6):e40255.

PMID: 39928768 PMC: 11813010. DOI: 10.1097/MD.0000000000040255.

The efficacy of traditional Chinese medicine sequential therapy in non-alcoholic fatty liver disease.

Zhang L, Qian Y, Wu H, Xu H Pak J Med Sci. 2025; 41(2):512-518.

PMID: 39926655 PMC: 11803795. DOI: 10.12669/pjms.41.2.11352.

Patent research in academic literature. Landscape and trends with a focus on patent analytics.

Mejia C, Kajikawa Y Front Res Metr Anal. 2025; 9():1484685.

PMID: 39844863 PMC: 11751822. DOI: 10.3389/frma.2024.1484685.

Bioinformatics based exploration of the anti-NAFLD mechanism of Wang's empirical formula via TLR4/NF-κB/COX2 pathway.

Chen S, Zhou C, Huang J, Qiao Y, Wang N, Huang Y Mol Med. 2024; 30(1):278.

PMID: 39730994 PMC: 11673956. DOI: 10.1186/s10020-024-01022-3.

References

Yin G, Liang H, Sun W, Zhang S, Feng Y, Liang P . Shuangyu Tiaozhi decoction alleviates non-alcoholic fatty liver disease by improving lipid deposition, insulin resistance, and inflammation and . Front Pharmacol. 2022; 13:1016745. PMC: 9727266. DOI: 10.3389/fphar.2022.1016745. View

Huang L, Zhu H, Tang Y, Luo Z, Xia L, Zhang C . Exploring the mechanism of Cassiae semen in regulating lipid metabolism through network pharmacology and experimental validation. Biosci Rep. 2023; 43(2). PMC: 9905789. DOI: 10.1042/BSR20221375. View

Nogales C, Mamdouh Z, List M, Kiel C, Casas A, Schmidt H . Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci. 2021; 43(2):136-150. DOI: 10.1016/j.tips.2021.11.004. View

Wang L, Zhi Y, Ye Y, Zhang M, Mai Z, Xia W . Metabolomic analysis identifies the regulation of lipid metabolism pathway as potential mechanisms of Jiangzhi decoction against non-alcoholic fatty liver disease. J Pharm Pharmacol. 2023; 75(10):1366-1377. DOI: 10.1093/jpp/rgad067. View

Wu Q, Yang F, Tang H . Based on network pharmacology method to discovered the targets and therapeutic mechanism of Paederia scandens against nonalcoholic fatty liver disease in chicken. Poult Sci. 2020; 100(1):55-63. PMC: 7772706. DOI: 10.1016/j.psj.2020.09.087. View

Kim S, Chen J, Cheng T, Gindulyte A, He J, He S . PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 2018; 47(D1):D1102-D1109. PMC: 6324075. DOI: 10.1093/nar/gky1033. View

Szklarczyk D, Santos A, von Mering C, Jensen L, Bork P, Kuhn M . STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2015; 44(D1):D380-4. PMC: 4702904. DOI: 10.1093/nar/gkv1277. View

Choudhry Q, Kim J, Cho H, Heo W, Lee J, Lee J . Ameliorative effect of black ginseng extract against oxidative stress-induced cellular damages in mouse hepatocytes. J Ginseng Res. 2019; 43(2):179-185. PMC: 6437468. DOI: 10.1016/j.jgr.2017.10.003. View

Shi H, Qiao F, Huang K, Lu W, Zhang X, Ke Z . Exploring therapeutic mechanisms of San-Huang-Tang in nonalcoholic fatty liver disease through network pharmacology and experimental validation. J Ethnopharmacol. 2022; 296:115477. DOI: 10.1016/j.jep.2022.115477. View

10.

Li Y, Li W, Fu C, Song Y, Fu Q . Lonicerae japonicae flos and Lonicerae flos: a systematic review of ethnopharmacology, phytochemistry and pharmacology. Phytochem Rev. 2020; 19(1):1-61. PMC: 7088551. DOI: 10.1007/s11101-019-09655-7. View

11.

Luo Z, Liu Y, Han X, Yang W, Wang G, Wang J . Mechanism of in the Treatment of Non-alcoholic Fatty Liver Disease Based on Sequential Metabolites Identification Approach, Network Pharmacology, and Binding Affinity Measurement. Front Nutr. 2021; 8:677659. PMC: 8481579. DOI: 10.3389/fnut.2021.677659. View

12.

Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S . The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics. 2016; 54:1.30.1-1.30.33. DOI: 10.1002/cpbi.5. View

13.

Huang S, Mu F, Li F, Wang W, Chen H, Lei L . A Network-Based Approach to Explore the Mechanism and Bioactive Compounds of Erzhi Pill against Metabolic Dysfunction-Associated Fatty Liver Disease. J Diabetes Res. 2020; 2020:7867245. PMC: 7382733. DOI: 10.1155/2020/7867245. View

14.

Chandran U, Patwardhan B . Network ethnopharmacological evaluation of the immunomodulatory activity of Withania somnifera. J Ethnopharmacol. 2016; 197:250-256. DOI: 10.1016/j.jep.2016.07.080. View

15.

Snel B, Lehmann G, Bork P, Huynen M . STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. Nucleic Acids Res. 2000; 28(18):3442-4. PMC: 110752. DOI: 10.1093/nar/28.18.3442. View

16.

Gong M, Su C, Fan M, Wang P, Cui B, Guo Z . Mechanism by which Eucommia ulmoides leaves Regulate Nonalcoholic fatty liver disease based on system pharmacology. J Ethnopharmacol. 2021; 282:114603. DOI: 10.1016/j.jep.2021.114603. View

17.

Li B, Xiao Q, Zhang J, Wang Y, Liu J, Zhang B . Exploring the active compounds and potential mechanism of the anti-nonalcoholic fatty liver disease activity of the fraction from Schisandra chinensis fruit extract based on multi-technology integrated network pharmacology. J Ethnopharmacol. 2022; 301:115769. DOI: 10.1016/j.jep.2022.115769. View

18.

Wang C, Chen H, Li Y, Zhou M, Wong V, Jiang Z . Network Pharmacology Exploration Reveals Anti-Apoptosis as a Common Therapeutic Mechanism for Non-Alcoholic Fatty Liver Disease Treated with Blueberry Leaf Polyphenols. Nutrients. 2021; 13(11). PMC: 8621134. DOI: 10.3390/nu13114060. View

19.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

20.

Zhang M, Yuan Y, Zhou W, Qin Y, Xu K, Men J . Network pharmacology analysis of Chaihu Lizhong Tang treating non-alcoholic fatty liver disease. Comput Biol Chem. 2020; 86:107248. DOI: 10.1016/j.compbiolchem.2020.107248. View